Developmental and Phenotypic Outcomes in Mild Phenylalanine Hydroxylase Deficiency
American Journal of Medical Genetics Part A · 2026-08 · 200 (8) · 1814-1820
DOI: 10.1002/ajmg.a.70154 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 05.04.2026. Verfasst von Aaron Williams und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Phenylketonurias, Phenylalanine, Phenylalanine Hydroxylase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Benign hyperphenylalaninemia (bHPA) is defined as elevated phenylalanine (Phe) levels remaining ≤ 360 μmol/L (6 mg/dL) and not requiring medical intervention. Individuals with bHPA may demonstrate a rise in their Phe levels > 360 μmol/L, effectively developing a mild PKU phenotype requiring therapy to prevent neurocognitive complications. This study aimed to identify risk factors for elevation of Phe > 360 μmol/L and the long‐term outcome of bHPA. Retrospective chart review at a single center identified thirty‐four individuals with bHPA. Among this group, twelve individuals ultimately demonstrated Phe levels > 360 μmol/L, thus defined as “Risers”, as opposed to the “Non‐Risers” that remained within bHPA range. Mean Phe level at first newborn screen (NBS) was higher in the Risers group. Clinical assessment pointed to developmental or behavioral issues in two‐thirds of the Risers, whereas all Non‐Risers had typical development. Our data suggest that bHPA may be associated with increased risk for neurodevelopmental complications among individuals who eventually developed Phe levels > 360 μmol/L. This study emphasizes that individuals with bHPA should be closely followed to track Phe levels and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
- Texas Children's Hospital, Houston, Texas, USA.
- Joint BCM-CUHK Center of Medical Genetics, Prince of Wales Hospital, Hong Kong SAR, China.
- Baylor Genetics, Houston, Texas, USA.
ORCID-Profile: Aaron Williams, Fernando Scaglia, V Reid Sutton, Ronit Marom
Zitieren
APA
Williams, A., Divin, K., Burrage, L. C., Craigen, W. J., Scaglia, F., Soler-Alfonso, C., Sutton, V. R., Glinton, K. E., & Marom, R. (2026). Developmental and Phenotypic Outcomes in Mild Phenylalanine Hydroxylase Deficiency. American Journal of Medical Genetics Part A, 200(8), 1814-1820. https://doi.org/10.1002/ajmg.a.70154
Vancouver
Williams A, Divin K, Burrage LC, Craigen WJ, Scaglia F, Soler-Alfonso C, et al. Developmental and Phenotypic Outcomes in Mild Phenylalanine Hydroxylase Deficiency. American Journal of Medical Genetics Part A. 2026;200(8):1814-1820. doi:10.1002/ajmg.a.70154
BibTeX
@article{Williams2026,
author = {Williams, Aaron and Divin, Kristian and Burrage, Lindsay C and Craigen, William J and Scaglia, Fernando and Soler-Alfonso, Claudia and Sutton, V Reid and Glinton, Kevin E and Marom, Ronit},
title = {Developmental and Phenotypic Outcomes in Mild Phenylalanine Hydroxylase Deficiency},
journal = {American Journal of Medical Genetics Part A},
year = {2026},
volume = {200},
number = {8},
pages = {1814--1820},
doi = {10.1002/ajmg.a.70154}
}
EUVIMED